Main > > >GASTRIC CANCER.

AdenoCarcinoma. Treat.: DoceTaxel Inj.+
Cisplatin+Fluorouracil.
USA Initial Approval Year: 1996.
(*) Company : sanofi-aventis U.S. LLC
TradeMark: Taxotere.
UpDate: 2018. 10.01.




AdenoCarcinoma. Treat.: DoceTaxel Inj.
Alcohol-Free+Cisplatin+Fluorouracil.
USA Approval Date: 2015. 12.28.
USA Launch Date: 2016. 02.02.
(*) Company; Patents; PR Web-Site &
TradeMark Available on Request.
UpDate: 2018. 10.29.




AdenoCarcinoma. Treat.: Mitomycin for Injection. Generic.
USA Launch Date: 2018. 03.20.
(*) Company : Mylan NV.
UpDate: 2018. 10.01.




AdenoCarcinoma. Treat.: TrastuzuMAb Deruxtecan.
(locally advanced or metastatic HER2-+)
USA Approval Date: 2021. 01.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.10.




AdenoCarcinoma. Treat.: Trifluridine+ Tipiracil Tablets.
(METASTATIC)
>Previously Treat.>2 CT>Fluoropyrimi-dine, a Platinum, either a Taxane or Irinotecan, ..
USA Approval Date: 2019. 02.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.26.




Companion Diagnostics.
"Biopsy>Liquid Biopsy CTCs+ctDNA"
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 06.12.




Companion Diagnostics. c-METASTATIC.
Amplified+. Liquid Biopsy>Blood Test.
USA Launch Date: 2015. 05.04.
(*) Company: BioCept Inc.
UpDate: 2018. 10.02.




Diagnostics. Capsule Endoscopy.
Magnetically Controlled Robotic Capsule
Endoscope.
CN Approval Year: 2013.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.30.




Treat.: NivoluMAb. (Metastatic or Recu-
rrent).
>Progressed After CT.
>UnResectable.
JP Approval Date: 2017. 09.22.
(*) Company : Bristol Myers Squibb.
TradeMark: Opdivo
Web-Site : www.opdivo.com
UpDate: 2018. 10.02.




Treat.: PembrolizuMAb. (METASTATIC or
Recurrent PD-L1+).
>& If .. HER2/neu-Targeted Therapy.
>2 Prior Fluoropyrimidine- & Pt-CT.
Companion Diagnostics>
>USA Approval Date: 2017. 09.22.
USA Approval Date : 2017. 09.22.
(*) Companies; TradeMarks; USA Patent
APP.; USA Patents & Web-Sites Avai-
lable on Request.
UpDate: 2020. 01.02.




Treat.: Rivoceranib (Apatinib).
CN Approval Date: 2014. 12.
(*) Company : LSK Biopharma.
Web-Site
lskbiopharma.com/rivoceranib-
apatinib/
UpDate: 2018. 10.01.




Treat.: TrastuzuMAb. BioSimilar.
(METASTATIC).
USA Launch Date: 2019. 07.18.
(*) Company : Amgen.
TradeMark: KANJINTI
UpDate: 2019. 11.12.




Treat.: TrastuzuMAb. BioSimilar.
(METASTATIC).
USA Launch Date: 2019. 12.02.
(*) Companies : Mylan NV & BioCon Ltd.
TradeMark : Ogivri.
UpDate: 2020. 01.02.




Treat.: TrastuzuMAb. BioSimilar.
(METASTATIC)
USA Approval Date: 2019. 03.11.
(*) Company : Pfizer
TradeMark: TRAZIMERA
UpDate: 2019. 03.13.




Treat.: TrastuzuMAb. BioSimilar.
(METASTATIC)
EU Approval Date : 2017. 11.20.
USA Approval Date: 2019. 01.21.
USA Launch Date: 2020. 04.15.
(*) Company : Merck (USA)
Company : Samsung Bioepis Co. Ltd.
TradeMark: ONTRUZANT
UpDate: 2020. 04.16.




Treat.: TrastuzuMAb. BioSimilar.
(METASTATIC)
USA Launch Date: 2020. 03.16.
(*) Company : Teva Pharma
TradeMark: HERZUMA
UpDate: 2020. 03.17.




Treat.: TrastuzuMAb DeruxTecan Inj.
(METASTATIC; HER2+)
JP Approval Date: 2020. 09.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request
UpDate: 2020. 09.27.


>GASTRIC CANCER.'s products
This section has no products